Cerevance thik-1
WebNov 7, 2024 · Cerevance BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced... WebNov 30, 2024 · Presentation highlights a novel target identified for Alzheimer's disease using Cerevance's proprietary NETSseq platform Cerevance's THIK-1 targeting inhibitor, C101248, demonstrated positive...
Cerevance thik-1
Did you know?
WebNov 30, 2024 · Cerevance is a private pharmaceutical company whose lead therapeutic, CVN424, a first-in-class, oral, non-dopaminergic compound acting on a novel target … WebNov 15, 2024 · C101248, Cerevance’s novel inhibitor, demonstrated a concentration-dependent inhibition of the protein in human and mouse cells expressing THIK-1 with …
WebDec 16, 2024 · Dec. 16, 2024 Investigators from Cerevance Inc. have reported the discovery and preclinical characterization of a novel tandem pore domain halothane-inhibited K+ channel 1 (THIK-1) inhibitor, C-101248, being developed for the treatment of neuroinflammation in Alzheimer’s disease (AD). WebApr 13, 2024 · Cerevance. BOSTON, April 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced ...
WebNov 15, 2024 · The presentation entitled “ Identification of THIK-1 as a Therapeutic Target For Alzheimer’s Disease: Characterisation of a Selective and Novel Blocker,” demonstrated the power of the proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform in identifying a novel target. Key highlights of the presentation include: WebNov 15, 2024 · – Data demonstrated C101248 is a promising inhibitor of THIK-1, an emerging target in Alzheimer’s disease –– THIK-1 was identified using Cerevance’s proprietary NETSseq platform ...
WebCerevance today announced a poster presentation at the BritishNeuroscience Association (BNA) 2024 International Festival of Neuroscience inBrighton, United Kingdom being held April 23-26, 2024 ... Title: NETSseq platform identifies KCNK13 (THIK-1) as a target to modulate neuroinflammation in Alzheimer’s disease . Overview: The NETSseq ...
WebMar 21, 2024 · The discovery of a THIK-1 inhibitor, C101248, and its pharmacological profile, as well as its effect in microglia, is explored. Presenter: Anna Rowland, PhD Session Date and Time: March 27, 2024, 1:30-2:45pm Binding Kinetics and Mechanistic PK/PD Modelingin Early Drug Discovery Conference Poster Details brother jon\u0027s bend orWeb1 day ago · BOSTON, April 13, 2024 (GLOBE NEWSWIRE) -- Cerevance a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a poster presentation at the British Neuroscience Association (BNA) 2024 International Festival of Neuroscience in Brighton, United Kingdom being … brother justus addressWeb1 day ago · Title: NETSseq platform identifies KCNK13 (THIK-1) as a target to modulate neuroinflammation in Alzheimer’s disease . Overview: The NETSseq platform can identify novel druggable microglia targets, exemplified by KCNK13, as potential therapies for neurodegenerative diseases. The discovery of a KCNK13 inhibitor, C101248, is described. brother juniper\u0027s college inn memphisWebNov 15, 2024 · BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous … brother kevin ageWebNov 30, 2024 · Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to … brother justus whiskey companyWebApr 13, 2024 · Title: NETSseq platform identifies KCNK13 (THIK-1) as a target to modulate neuroinflammation in Alzheimer’s disease Overview: The NETSseq platform can identify novel druggable microglia targets, exemplified by KCNK13, as potential therapies for neurodegenerative diseases. The discovery of a KCNK13 inhibitor, C101248, is described. brother keepers programWebCerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease Data has been concurrently published in the peer-reviewed journal, Neuropharmacology brother jt sweatpants